Immune Checkpoint Inhibitors in Cancer Focusing on Urogenital Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (8 November 2021) | Viewed by 11101
Special Issue Editor
Special Issue Information
Dear Colleagues,
Immunotherapy alone or in combination with systemic or targeted therapy has revolutionized cancer treatment, becoming a therapeutic mainstay in various cancer entities, such as urogenital tumors. As an example, treatment with Bacillus Calmette–Guérin (BCG) belongs to the most successful cancer immunotherapies in high-risk, non-muscle-invasive bladder cancer for more than forty years. Although immunotherapy has dramatically expanded the therapeutic landscape in metastatic RCC and bladder cancer, biomarkers in predicting response to checkpoint inhibitors such as PD-L1 are still inconclusive, with discordant results. This Special Issue welcomes original articles and reviews about current treatment guidelines on checkpoint inhibition in urogenital cancers and novel molecular, genetic, and soluble biomarkers in predicting response and survival to checkpoint inhibitors.
Dr. Renate Pichler
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urothelial cancer
- renal cell carcinoma
- prostate cancer
- immunotherapy
- predictive and prognostic biomarkers
- BCG
- soluble immunological biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.